<DOC>
	<DOCNO>NCT00682760</DOCNO>
	<brief_summary>To compare efficacy safety Korean botulinum toxin A ( KbtxA , Pacific Pharmaceuticals , Korea ) Botox treatment essential blepharospasm , perform double-blinded , randomize , comparative trial compare KbtxA Botox treatment blepharospasm 60 patient intention treat population 52 patient ( 26 patient group ) per protocol population . The improvement severity spasm ( SS ) 4 week post-injection primary efficacy outcome , qualify non inferiority control group , Changes eyelid closure force ( CF ) functional visual status ( FVS ) injection secondary efficacy outcome , adverse effect safety evaluation . Improvement SS note 90.3 % KbtxA group 86.2 % Botox group . There significant difference treatment group change CF FVS injection ( p &gt; 0.05 ) . Adverse effect develop 16.1 % KbtxA group 27.6 % Botox group , serious adverse event find either group . KbtxA inferior Botox treatment efficacy clinically safe serious adverse effect use treat essential blepharospasm .</brief_summary>
	<brief_title>Comparison Korean Botulinum Toxin Type A Versus Botox Treatment Essential Blepharospasm</brief_title>
	<detailed_description>Severity spasm grade clinically grade 0 4 . Primary efficacy outcome assess number ( % ) patient improve SS 1 score 4 week post-injection . Secondary efficacy outcome measure include change score baseline SS , close force eyelid , functional visual status 4 week post-injection . The duration action ( day ) , time interval injection moment patient felt need retreatment also assess secondary efficacy outcome . The number ( % ) patient improvement SS ( primary efficacy outcome ) change score baseline 4 week post-injection severity spasm , close force eyelid , functional visual status score different KbtxA Botox group analysis ITT PP population . Also , duration action similar follow KbtxA Botox injection ( two sample t-test , p=0.835 ) . For non-inferiority trial primary efficacy outcome , KbtxA inferior Botox either ITT PP population , low limit 95 % confidence interval ( -1.76 % ITT , -1.64 % PP ) -15 % threshold .</detailed_description>
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>All patient , age 18 75 year old , confirmed diagnose bilateral essential blepharospasm . The patient recruit two botulinum toxin clinic ( Yonsei University ChungAng University , Seoul , Korea ) October 18 , 2005 February 21 , 2006 . Patients eligible inclusion study undergone either myectomy neurectomy receive antispastic , muscle relaxant medication within 1 month study entry inject previously BTXA within 3 month study entry muscle disorder Women positive urine pregnancy test , pregnant lactating also exclude study . In addition , patient show hypersensitivity BTXA previously eligible inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Botulinum Toxin Type A</keyword>
	<keyword>Blepharospasm</keyword>
</DOC>